Cart
sales@molnova.com
L-165041
CAS No. 79558-09-1
L-165041( —— )
Catalog No. M20696 CAS No. 79558-09-1
L-165041 is a potent and selective agonist of the nuclear receptor PPARβ and PPARδ(Ki = 9 nM EC50 = ~500 nM respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 38 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 74 | In Stock |
|
| 25MG | 160 | In Stock |
|
| 50MG | 302 | In Stock |
|
| 100MG | 506 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameL-165041
-
NoteResearch use only, not for human use.
-
Brief DescriptionL-165041 is a potent and selective agonist of the nuclear receptor PPARβ and PPARδ(Ki = 9 nM EC50 = ~500 nM respectively).
-
DescriptionL-165041 is a potent and selective agonist of the nuclear receptor PPARβ and PPARδ(Ki = 9 nM EC50 = ~500 nM respectively).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number79558-09-1
-
Formula Weight402.44
-
Molecular FormulaC22H26O7
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL (124.24 mM)
-
SMILESCCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O
-
Chemical Name2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-acetic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Park J H Lee K S Lim H J et al. The PPARδ ligand L-165041 inhibits vegf-induced angiogenesis but the antiangiogenic effect is not related to PPARδ[J]. Journal of Cellular Biochemistry 2012 113(6):1947-1954.
molnova catalog
related products
-
Bezafibrate
Bezafibrate(BM15075) is the first clinically tested dual and pan-PPAR co-agonism.
-
Pemafibrate
A highly potent, specific PPARα agonist with EC50 of 1 nM.
-
BADGE
Bisphenol a diglycidyl ether is a Standardized Chemical Allergen. The physiologic effect of bisphenol a diglycidyl ether is by means of Increased Histamine Release, and Cell-mediated Immunity.
